DAVID QURAISHI: Open Payments
NPI 1982124574 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,987 in 101 payments from 24 companies in 2025. Trend: 2023 $1,730 · 2024 $2,400 · 2025 $1,987
Food & beverage: $1,987
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $332 |
| ABBVIE INC. | 15 | $253 |
| Novo Nordisk Inc | 16 | $238 |
| GlaxoSmithKline, LLC. | 10 | $186 |
| PFIZER INC. | 7 | $141 |
| Amgen Inc. | 6 | $100 |
| Sumitomo Pharma America, Inc. | 4 | $100 |
| Aimmune Therapeutics, Inc. | 4 | $93 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $61 |
| Astellas Pharma US Inc | 3 | $59 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, LINZESS, Ozempic, ELIQUIS, OTEZLA, GEMTESA, ZENPEP.
Industry payments across AZ — which companies pay providers there.
